We analysed the impact of older age on the management of immune thrombocytopenia (ITP) in 465 adult patients diagnosed between 1995 and 2017 and followed at our institution for a minimum of 12 months. Over a follow-up of 4248 patient-years, front-line corticosteroids therapy was required in 334 patients (71Á8%), mainly (85Á3%) within 1 year from diagnosis. Need for first-, second-and third-line therapy was comparable in younger and older (age ≥65 years, n = 154) patients. Older patients presented more frequently with severe haemorrhages, started therapy with a higher platelet count and received lower dose front-line corticosteroids; thereafter, they were preferentially treated with mild immunosuppressive therapies/thrombopoietin-receptor agonists. Conversely, younger patients were more frequently treated with rituximab and splenectomy, achieving higher rates of complete responses. Incidence rates of ≥grade 2 complications were: 2Á87 (haemorrhages), 1Á55 (infections) and 0Á66 (thromboses) per 100 patient-years. Older age (P = 0Á01) and active haemorrhages at diagnosis (P = 0Á01) significantly predicted grade ≥2 haemorrhages during follow-up. Older age (P = 0Á01), male gender (P = 0Á01), and thrombopoietin receptor agonist use (P = 0Á02) were significantly associated with a higher probability of thrombosis over time. Older age is a significant driver of diagnostic/therapeutic strategy in ITP resulting in different responses and complications rates.
Summary
We analysed the impact of older age on the management of immune thrombocytopenia (ITP) in 465 adult patients diagnosed between 1995 and 2017 and followed at our institution for a minimum of 12 months. Over a follow-up of 4248 patient-years, front-line corticosteroids therapy was required in 334 patients (71Á8%), mainly (85Á3%) within 1 year from diagnosis. Need for first-, second-and third-line therapy was comparable in younger and older (age ≥65 years, n = 154) patients. Older patients presented more frequently with severe haemorrhages, started therapy with a higher platelet count and received lower dose front-line corticosteroids; thereafter, they were preferentially treated with mild immunosuppressive therapies/thrombopoietin-receptor agonists. Conversely, younger patients were more frequently treated with rituximab and splenectomy, achieving higher rates of complete responses. Incidence rates of ≥grade 2 complications were: 2Á87 (haemorrhages), 1Á55 (infections) and 0Á66 (thromboses) per 100 patient-years. Older age (P = 0Á01) and active haemorrhages at diagnosis (P = 0Á01) significantly predicted grade ≥2 haemorrhages during follow-up. Older age (P = 0Á01), male gender (P = 0Á01), and thrombopoietin receptor agonist use (P = 0Á02) were significantly associated with a higher probability of thrombosis over time. Older age is a significant driver of diagnostic/therapeutic strategy in ITP resulting in different responses and complications rates.
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Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by an isolated platelet count below 100 9 10 9 / l, in the absence of any underlying cause or disorder (Cines & Blanchette, 2002; Rodeghiero et al, 2009) . ITP is caused by an autoantibody-mediated accelerated platelet destruction and impaired platelet production (Nugent et al, 2009) . ITP has long been considered as a disease affecting predominantly young or middle-aged women. However, its incidence increases with age and, along with older age, the sex ratio tends to normalize (Frederiksen & Schmidt, 1999; Kuhne et al, 2011; Moulis et al, 2014) . Corticosteroids are the current standard first-line treatment for all ITP patients with active haemorrhage and/or a platelet count <20-30 9 10 9 /l. Older age, comorbidities and patient lifestyle may increase the threshold of platelet count below which a treatment is required and/or may suggest a reduction of corticosteroids doses in order to decrease toxicity (Bellucci et al, 1988; Bizzoni et al, 2006; Provan et al, 2010; Neunert et al, 2011) . Older age may also influence the choice of second-line therapies, including immunosuppressive agents (Quiquandon et al, 1990; Reiner et al, 1995; Emilia et al, 2002) , danazole (Maloisel et al, 2004) , dapsone (Vancine-Califani et al, 2008) , splenectomy (Chaturvedi et al, 2018) , anti-CD20 monoclonal antibody rituximab (Godeau et al, 2008; Khellaf et al, 2014; Zhou et al, 2015) and the agonists of the thrombopoietin receptor (TPO-ra) romiplostim and eltrombopag (Bussel et al, 2007; Kuter et al, 2008; Wong et al, 2017) . In particular, splenectomy is generally associated with a lower risk of perioperative complications and of relapse in younger research paper First published online 8 November 2018 doi: 10.1111/bjh.15668 patients, who also achieve better responses with rituximab (Medeot et al, 2008; Gonzalez-Porras et al, 2013; Vianelli et al, 2013; Park et al, 2016; Marangon et al, 2017) . TPO-ra have shown a good efficacy profile regardless of age, but a drug-related thrombotic risk may be relevant (Michel, 2009; Michel et al, 2015) .
Impact of older age in the management of ITP has never been specifically investigated before. Here, we report the outcome of a large cohort of ITP patients, followed for a median period of longer than 8 years at a single institution, with the aim to describe the impact of age on ITP characteristics at diagnosis and type/timing of treatment strategy, including response and complications rates.
Methods
An electronic database was created in the 1980s, to collect clinical/laboratory data of ITP patients followed at the Institute of Haematology "L. and A. Ser agnoli" in Bologna, Italy. The database now includes data on over 800 patients diagnosed since 1980. Since 1990, data were prospectively collected and updated at 6-month intervals, as previously described (Palandri et al, 2016) . In order to increase data accuracy and to include only patients for which the same therapeutic options were available, the present analysis focused only on the 465 patients that were diagnosed between January 1995 and January 2017. Data cut-off was February 2018. ITP diagnosis was assessed according to standard criteria (isolated thrombocytopenia, normal or increased megakaryocyte count in an otherwise normal bone marrow aspirate and absence of other causes of thrombocytopenia) (Rodeghiero et al, 2009) .
Any treatment decision, at front-line and in case of resistance/relapse, was at the physician's discretion, based on patients' characteristics. Four patients were included in a phase 2 study (NCT 00770562) and received a front-line combination of dexamethasone and rituximab. Responses to all treatments and relapses were rated and classified according to current guidelines and terminology (Rodeghiero et al, 2009) . Haemorrhages and thrombosis were graded according to the World Health Organization criteria (Slichter, 2007) . All infections graded ≥2 (i.e. requiring systemic treatment) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 (https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf) were recorded. Infections were defined in accordance with the criteria of the U.S. Centers for Disease Control and Prevention (Horan et al, 2008) . The study was approved by the local Ethics Committee and was conducted in accordance with the Declaration of Helsinki.
Statistical analysis
Continuous variables have been summarized by their median and range, and categorical variables by count and relative frequency (%) of each category. Comparisons of quantitative variables between groups of patients were carried out by Wilcoxon-Mann-Whitney rank-sum test, and association between categorical variables (2-way tables) was tested by the Fisher exact test or v 2 , as appropriate. Bonferroni correction multiple comparison test was used to control familywise error rate. Overall, haemorrhage-free, infection-free and thrombosis-free survival analyses were conducted with the Kaplan-Meier method from the date of ITP diagnosis to the date of the respective event (death, haemorrhage, infection or thrombosis), or last contact, and compared by the logrank test. Univariable and multivariate analyses were performed using the Cox proportional hazards regression model and, before proceeding from univariable to multivariate analysis, collinearity amongst variables was detected by means of Pearson correlation test. Treatments were considered timeto-event variables, reported as Kaplan-Meier estimates and incidence rates. Incidence rates were compared by Exact mis-P estimation method. Time to first-line therapy was calculated from ITP diagnosis, while time to second-and thirdline therapies were calculated from the start of the previous therapy. Cumulative incidences of infections, haemorrhages and thromboses were calculated considering death as competing risk, according to the model of Fine and Gray. All P values were two-sided and statistical significance was defined as P < 0Á05. All statistical analyses were computed with STATA software v15 (StataCorp LLC, College Station, TX, USA).
Results

Study cohort
Overall, 465 consecutive ITP patients were diagnosed and followed between January 1995 and January 2017 at the "L. and A. Ser agnoli" Institute of Haematology, Bologna, Italy. All patients had a minimum follow-up of 12 months, for a total observation of 4248 patient-years. Median age at ITP diagnosis was 52 years (range, 16-94); 62% were females. The proportion of male to female patients progressively increased with older age, being 12Á6% in patients aged 16-29 years (n = 92) and 41% in patients ≥65 years (n = 154) (P = 0Á003). At diagnosis, 182 (41Á7%) patients presented with haemorrhages (grade 3-4 in 6Á6% of the cases). Haemorrhages were significantly associated with platelet count, being 76Á2%, 18Á8% and 5Á0% in patients with baseline platelet count <20 9 10 9 /l, 20-50 9 10 9 /l and >50 9 10 9 /l, respectively (P < 0Á001). Overall, a front-line therapy was required in 334 patients (71Á8%), with a total incidence rate of 1Á67 per 100 patientyears (95% confidence interval [CI]: 1Á50-1Á86). Treatment began at ITP diagnosis in 45% of patients and 85Á3% of treated patients commenced corticosteroid therapy within the first year from diagnosis. At treatment start, platelet count was below 30 9 10 9 /l in 94Á9% of the patients. In the remaining 17 patients, therapy was started when the platelet count was between 30 and 50 9 10 9 /l because of active haemorrhages (17Á6%), concomitant antiplatelet/anticoagulant therapy (47Á2%) or need to increase platelet count because of surgery/delivery.
Incidence rates of first-line therapy start progressively decreased over time, being 12Á3, 0Á6 and 0Á2 per 100 patientyears during the first, second and third year from diagnosis, respectively. The incidence rates of second-and third-line treatments were 1Á20 (95% CI: 1Á05-1Á38) and 1Á31 (95% CI: 1Á10-1Á56) per 100 patient-years, respectively.
Treatment strategies according to age at diagnosis
Overall, 154 out of 465 (33Á1%) patients were diagnosed with ITP when aged ≥65 years (elderly patients) ( Table I) . Despite comparable baseline platelet counts, the elderly presented a higher incidence of grade 3-4 haemorrhages (P = 0Á002). The incidence rate of first-line treatment was comparable across age groups, although median platelet count at therapy start was significantly higher in older patients (P = 0Á01).
The incidence rates of use of prednisone or dexamethasone alone for front-line therapy were, respectively, 1Á31 (95% CI: 1Á16-1Á48) and 0Á04 (95% CI: 0Á02-0Á08) per 100 patient-years. The remaining patients received prednisone in combination with other agents: incidence rates of prednisone therapy in combination with high-dose immunoglobulin, azathioprine or rituximab were, respectively, 0Á21 (95% CI: 0Á16-0Á29), 0Á08 (95% CI: 0Á05-0Á13) and 0Á02 (95% CI: 0Á01-0Á05) per 100 patient-years. Patients aged <65 years more frequently received a starting prednisone dose ≥0Á8 mg/kg/day (88Á9% vs. 69Á6% in older patients, P = 0Á005), while the median prednisone exposure was comparable in the two age-groups (P = 0Á68).
The incidence rates of second-and third-line treatments were comparable in younger and older patients. Second-line, the use of mild immunosuppressive agents and of rituximab were significantly higher in older and in younger patients, respectively (Fig 1A and B) . Third-line, the use of mild immunosuppressive agents was also significantly higher in the elderly (Fig 1C) , while only younger patients were splenectomized (Fig 1D) . Incidence rates of TPO-ra treatment tended to be higher in older patients at both secondline (0Á14 vs. 0Á05 per 100 patient-years, P = 0Á08) and thirdline (0Á27 vs. 0Á10 per 100 patient-years, P = 0Á08).
As rituximab and TPO-ra became available at our institution in 2002 and 2007 respectively, we performed a subgroup analysis according to date of diagnosis (before or after 2005). The use of rituximab was comparable between the patients diagnosed in these two periods (P = 0Á36). Conversely, patients diagnosed after 2005 were significantly more likely to be treated with TPO-ra compared to patients with earlier diagnosis (P = 0Á02). This was mainly due to a higher use of TPO-ra in older patients (23Á3% vs. 6Á7% in patients aged <65 years, P = 0Á01).
Responses and outcome according to age at diagnosis
Responses and failure rates of each individual treatment were tested according to age at diagnosis and resulted comparable in younger and older patients (Table SI) .
At last contact, 238 out of 334 (84Á3%) treated patients were off therapy because of stable responses or multi-resistance (3 patients). The remaining 96 patients were on chronic therapy, specifically: prednisone (41Á7%), TPO-ra (21Á9%), prednisone combined with azathioprine (15Á6%) and azathioprine alone (20Á8%). The type of continuous therapy was equally distributed in the two groups (P = 0Á23). However, the percentage of elderly patients in drug-dependent response was significantly higher compared to younger group (32Á5% vs. 14Á8%, P < 0Á001). Also, the complete response rate was significantly lower in the elderly (61Á3% vs. 76Á6%, P = 0Á006). One hundred and twenty-two haemorrhages were observed in 83 patients (36%: grade 2; 45Á5%: grade ≥3). Sixty-six infections were observed in 44 patients (54Á5%: grade 2; 45Á5%: grade ≥3). Infections involved mainly the lungs (47%) and urinary tract (16Á7%). Only 4 infections occurred in patients that never received immunosuppressive therapy for ITP. A total of 28 thromboses (arterial: 78Á6%, including 12 acute myocardial infarctions and 5 stokes) occurred in 24 patients (21Á4%: grade 2; 78Á6%: grade ≥3).
Incidence rate of ≥grade 2 complications were: 2Á87 per 100 patient-years (haemorrhages), 1Á55 per 100 patient-years (infections) and 0Á66 per 100 patient-years (thromboses). After adjustment for the risk of death, the cumulative incidence of grade 3-4 haemorrhages and thromboses was significantly higher in the elderly (Fig 2A and C) . Conversely, the cumulative incidence of grade 3-4 infections was comparable in the two age-groups (Fig 2B) .
Older age (P = 0Á01) and active haemorrhages at diagnosis (P = 0Á01) significantly predicted grade ≥2 haemorrhages during follow-up (Table SII) . Analogously, a more aggressive disease presentation (specifically, platelet count below 20 9 10 9 /l and active haemorrhages requiring therapy) was significantly associated with subsequent infections. Finally, older age (P = 0Á01) and male gender (P = 0Á01) were Probability of receiving selected second and third-line therapies according to age at diagnosis. The incidence rate of second-line therapy with mild immunosuppressive agents (AZA, azathioprine; EDX, endoxan; CSA, ciclosporin A) was significantly higher in the elderly (0Á14 per 100 patient-years, 95% confidence interval [CI]: 0Á07-0Á29 vs. 0Á03 per 100 patient years, 95% CI: 0Á01-0Á09, P = 0Á02) (A). Conversely, a significantly higher incidence rate of second-line Rituximab was observed in younger patients (0Á21 per 100 patient-years, 95% CI: 0Á14-0Á31 vs. 0Á06 per 100 patient years, 95% CI: 0Á02-0Á18, P = 0Á02) (B). The incidence rate of third-line mild immunosuppressive agents was significantly higher in the elderly (0Á19 per 100 patient-years, 95% CI: 0Á08-0Á46 vs. 0Á04 per 100 patient years, 95% CI: 0Á01-0Á13, P = 0Á04) (C). The incidence rate of thirdline splenectomy in younger patients was 0Á18 (95% CI: 0Á10-0Á31, P = 0Á02) (D significantly associated with a higher probability of thrombosis over time. TPO-ra use significantly increased the risk of subsequent thromboses (P = 0Á02). At last contact, 46 (9Á9%) patients had died after a median time from ITP diagnosis of 90 months (range, 13-214). As expected, Kaplan-Meier analysis showed that elderly patients had a significantly worse overall survival compared to younger patients (log-rank P < 0Á001, 89Á8% vs. 98Á6% at 5 years, respectively).
Causes of death were: thrombosis (19Á6%), solid neoplasia (15Á2%), haemorrhages (8Á7%), haematological neoplasia (6Á5%), congestive heart failure (6Á5%), infections (n = 2, 4Á4%), multiple organ failure (n = 2), old age (n = 9) and other unrelated causes (n = 7). Among deaths due to thrombotic events, one acute myocardial infarction and one peripheral arterial thrombosis occurred in patients with platelet count <50 9 10 9 /l (one patient untreated and one under active ITP therapy with prednisone and azathioprine). Two fatal haemorrhages occurred when platelet count was below 30 9 10 9 /l. The 3 haematological malignancies (2 non-Hodgkin lymphomas, 1 myelodysplastic syndrome) occurred after more than 5 years from ITP diagnosis, which had been previously confirmed by bone marrow biopsy. The two patients who died due to pulmonary infections were not receiving immunosuppressive therapy for ITP.
Discussion
The first result of this study is that ITP presented as a more aggressive disease in older patients, who more frequently experienced severe haemorrhages and needed to start corticosteroid therapy with a higher platelet count. Additionally, although the current recommendation is to perform bone marrow examination in older individuals (British Committee for Standards in Haematology General Haematology Task Force 2003, Cines & Bussel, 2005; Provan et al, 2010; Neunert et al, 2011) , in this cohort, it was more commonly performed in younger patients. This real-life practice reflects the Cumulative incidences were calculated with Fine and Gray Competing risks regression, with death as competitive risk. At 2 years, the cumulative incidence of grade-3/4 haemorrhages, infections, and thromboses was 3%, 3Á35% and 3Á3% in the elderly, compared to 0Á2%, 2Á3% and 0Á9% in the younger (P = 0Á01, P = 0Á40 and P = 0Á01, respectively). [Colour figure can be viewed at wileyonlinelibrary.com] postponement of biopsy in older subjects until failure of first-line therapy; also, marrow biopsy was always performed before splenectomy, preferentially executed in patients aged <65 years. The second result is that older age was a crucial factor in therapeutic decision-making. Younger patients were more frequently underwent a boosted immunosuppressive therapy, including higher dosages of corticosteroids front-line and rituximab and/or splenectomy thereafter (Mahevas et al, 2016) . This approach could more frequently achieve a "cure" in younger patients, while the elderly presented a significantly higher rate of drug-independent responses at last contact. However, the failure rate of each therapeutic strategy was not influenced by age, confirming that the quality of the response is the main determinant of stable responses (Vianelli et al, 2013) .
Finally, we observed an excess of severe haemorrhages in older patients. The association between age and risk of haemorrhage may be linked to patient frailty and comorbidities, concomitant medications including antiplatelet/anticoagulant therapy, or to a more aggressive form of ITP (Vianelli et al, 2001; Bizzoni et al, 2006; Moulis et al, 2014; Mahevas et al, 2016) . Additionally, older age, male gender and use of TPO-ra correlated with increased rate of subsequent severe thromboses. Further studies may clarify whether the higher incidence of thrombotic complications in the elderly depends on ITP itself, age, treatment or all three factors (Cuker, 2010; Catala-Lopez et al, 2015; Rodeghiero, 2016) .
Overall, this retrospective study shows that older age may influence ITP presentation, diagnostic/therapeutic strategies and outcome. Larger clinical trials investigating age-adapted treatment strategies should be further explored in ITP patients.
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